Skip to main content
Oxurion NV logo

Oxurion NV — Investor Relations & Filings

Ticker · OXUR ISIN · BE0974487192 LEI · 549300VWY8KVDFKLDM59 BR Professional, scientific and technical activities
Open in API
Filings indexed 1,031 across all filing types
Latest filing 2015-04-03 AGM Information
Country BE Belgium
Listing BR OXUR

About Oxurion NV

https://oxurion.com/

Oxurion NV is a company focused on acquiring majority stakes in European pharmaceutical subcontractors. Its strategy is to build an integrated group of contract service providers to support healthcare stakeholders. A key asset in its portfolio is a majority stake in Axiodis CRO, a contract research organization specializing in biometrics. This investment-based business model represents a strategic pivot from the company's former focus on the internal research and development of therapies for retinal diseases such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Recent filings

Filing Released Lang Actions
THR_notulen_AV05052015.pdf
AGM Information Classification · 100% confidence The document text explicitly states in the header: "Notulen van de jaarlijkse algemene vergadering van aandeelhouders gehouden op 5 mei 2015" (Minutes of the annual general meeting of shareholders held on May 5, 2015). The content details the composition of the bureau, calling procedures, attendance, and lists specific agenda items and resolutions voted upon during this meeting, such as approving the annual accounts and granting discharge to directors. This content perfectly matches the definition of AGM materials, specifically the official minutes of the meeting. Therefore, the classification is AGM-R.
2015-04-03 Dutch
TG GLOBAL - Annual Report of the Board of Directors on the consolidated financial statements 2014 - signed.pdf
Annual Report Classification · 95% confidence The document is titled 'Annual Report of the Board of Directors on the Consolidated Financial Statements' and provides a comprehensive review of the company's financial performance, including profit and loss accounts, cash flow, risk management, and board activities for the fiscal year 2014. It contains substantive financial data and management analysis, fitting the definition of an Annual Report (10-K) or a comprehensive management report. Given the structure and content, it is a primary annual reporting document. FY 2014
2015-04-03 English
ThromboGenics_AR2014_FinVerslag_NL_FINAL_spreads.pdf
Annual Report Classification · 100% confidence The document is explicitly titled 'jaarverslag' (Annual Report) and contains comprehensive financial information for the fiscal year 2014, including consolidated balance sheets, profit and loss statements, management reports, and auditor information. It is a full-length annual report, not an announcement or a summary, and thus fits the definition of a 10-K (Annual Report). FY 2014
2015-04-03 Dutch
CV Emmanuele Attout_2014.pdf
Board/Management Information Classification · 92% confidence The document provided is a detailed curriculum vitae (CV) or professional biography for an individual named Emmanuèle Attout. It outlines her academic background, professional experience (especially as an auditor and partner at PwC), leadership roles, and other activities, including board experience and NGO involvement. This type of document is not a standard regulatory filing like a 10-K, ER, or IR. It most closely resembles background information that might be provided in connection with a board appointment, a proxy statement (DEF 14A, which covers remuneration/directors), or general governance documentation. Since the content focuses heavily on professional qualifications, audit history, and board involvement, it strongly relates to Board/Management Information (MANG) or Governance Information (CGR). Given the detailed professional history and focus on qualifications for roles like statutory auditor and board director, MANG (announcement of changes in management/board) is a strong fit, as this CV would likely accompany such an announcement. It could also be part of a DEF 14A (Remuneration/Director info), but MANG is broader for management profiles. I will classify it as MANG as it details the background of a key individual.
2015-04-03 English
THR_-#10101741-v1-THR_-_Proxy_(DUTENG)_NL.pdf
AGM Information Classification · 99% confidence The document is explicitly titled 'VOLMACHT' (Proxy) in Dutch and 'PROXY' in the English translation. It details the process for a shareholder to grant authority to a representative ('Gevolmachtigde'/'Proxy Holder') to attend and vote at the 'jaarvergadering' (annual meeting). The agenda items confirm this relates to an annual meeting, covering the review of the annual report, approval of remuneration reports, approval of annual accounts for the year ended December 31, 2014, discharge of directors, and appointment of a new director. This document is the formal proxy form used to facilitate voting at the Annual General Meeting (AGM). Therefore, it falls under the AGM Information category.
2015-04-03 Dutch
R ThromboGenics NV IFRS Report on the consolidated financial statements - unmodified opinion ENG.pdf
Audit Report / Information Classification · 99% confidence The document explicitly contains the title "Statutory auditor's report to the General Shareholders Meeting on the consolidated financial statements for the year ended 31 December 2014". It details the audit procedures, expresses an unqualified opinion on the consolidated financial statements prepared under IFRS, and is signed by the statutory auditor (BDO). This content perfectly matches the definition of an Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles, distinguishing it from a full Annual Report (10-K) or a simple announcement (RPA/RNS). FY 2014
2015-04-03 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.